VIRX (Viracta) Forward P/E Multiple

Official company branding of Viracta Therapeutics, Inc. (VIRX)

Viracta Therapeutics is implementing ethical ESG standards into the development of anti-cancer agents, and on GURU.Markets, the company's forward P/E ratio confirms a trend with the metric standing at 0.00. The business capitalization relies on the future commercialization of Epstein-Barr virus therapy, while production facilities and research centers operate in accordance with strict international sterility regulations.

viracta.com - VIRX Forward P/E Multiple (period 07/04/2022 - 02/16/2025)

Summary analytical data breakdowns for Viracta Therapeutics, Inc. (VIRX)

General company analysis:viracta.com
Brand item of viracta.com

For Viracta Therapeutics (VIRX), the forward P/E measures the market value of the business through the lens of expected earnings, accounting for the potential to set high prices for orphan cancer therapy drugs. By analyzing the fluctuations in the company's forward P/E, an investor gains a real-time assessment of future cash flows, making it possible to timely identify whether the asset is overbought or to find an entry point before the biotech giant realizes its pricing power.

Main competitors

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|CRIS - Market Cap to Projected Earnings|Projected Price to Earnings APLM|Tharimmune (THAR) - Market Cap to Projected Earnings|Projected Price to Earnings ADVB (Advanced Biomed Inc.)|Genprex - Price to Future Earnings Ratio|Forward P/E Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Projected Price to Earnings|Xenetic Bio - Forward P/E Multiple|SLRX - Forward P/E Multiple|PPBT: Forward P/E Multiple|Price to Future Earnings Ratio AONC|BGNE (BeiGene Ltd) - Forward P/E Multiple|CKPT (Checkpoint Therapeutics, Inc) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ELEV|Projected Price to Earnings iCAD Corp ICAD|Future Price to Earnings ikenaoncology.com IKNA|NTBL - Projected Price to Earnings|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple